On July 18, 2025, iTeos Therapeutics, Inc. entered a merger agreement with Concentra Biosciences where shareholders will receive $10.047 per share in cash and contingent value rights related to future earnings; it will lead to iTeos becoming a subsidiary of Concentra. The merger is contingent upon Concentra acquiring over 50% of shares and having a minimum closing net cash of $475 million.